Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2072539 | 0.78 | ADORA2A (0.48) | ALDH1A1MAPTADORA2AADORA2BKMT2A | |
| SCHEMBL4458152 | 0.74 | PARP1 (0.47) | MAPT | |
| SCHEMBL30530627 | 0.72 | ALDH1A1 (0.72) | ALDH1A1MAPTADORA2AADORA2BKMT2A | |
| SCHEMBL13442506 | 0.69 | KMT2A (0.42) | ALDH1A1MAPTADORA2AADORA2BKMT2A | |
| SCHEMBL4456746 | 0.69 | HPGD (0.64) | ALDH1A1KMT2AMEN1HPGDLMNA | |
| SCHEMBL8530149 | 0.67 | ADORA2A (0.53) | ALDH1A1ADORA2AADORA2BKMT2AGAA | |
| SCHEMBL1190927 | 0.66 | — | — | |
| SCHEMBL3797438 | 0.65 | POLB (0.53) | ALDH1A1KMT2AGAAHPGDPDE3B | |
| SCHEMBL1040106 | 0.65 | — | — | |
| SCHEMBL10838564 | 0.64 | KDM4E (0.48) | ALDH1A1MAPTADORA2AADORA2BKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048276-A1 | Inhibitors of Fatty Acid Synthase (Fas) | MERCK SHARP & DOHME CORP. | 2009-02-19 | — | — | US | disclosed |
| US-20090048276-A1 | Inhibitors of Fatty Acid Synthase (Fas) | MERCK SHARP & DOHME CORP. | 2009-02-19 | — | — | US | disclosed |
| US-20090048276-A1 | Inhibitors of Fatty Acid Synthase (Fas) | MERCK SHARP & DOHME CORP. | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048276-A1 | Inhibitors of Fatty Acid Synthase (Fas) | FASN, FADS2, FADS1 | ALDH1A1 575/4885MAPT 4736/4885ADORA2A 3592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.